Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug;169(1):11-23.
doi: 10.1007/s11060-024-04631-4. Epub 2024 Jun 20.

Dosimetric evaluation and treatment planning considerations for GammaTile permanent brain implants - a pilot, institutional experience

Shunqing Zhang  1 , Krishnan Patel  2 , Kathryn Dusenbery  3 , Abdullah Alshreef  3 , David Sterling  3 , Lindsey Sloan  3 , Margaret Reynolds  3 , Clark C Chen  4 , Clara Ferreira  5
Affiliations

Dosimetric evaluation and treatment planning considerations for GammaTile permanent brain implants - a pilot, institutional experience

Shunqing Zhang et al. J Neurooncol. 2024 Aug.

Abstract

Purpose: GammaTile® (GT) is a brachytherapy platform that received Federal Drug Administration (FDA) approval as brain tumor therapy in late 2018. Here, we reviewed our institutional experience with GT as treatment for recurrent glioblastomas and characterized dosimetric parameter and associated clinical outcome.

Methods and materials: A total of 20 consecutive patients with 21 (n = 21) diagnosis of recurrent glioblastoma underwent resection followed by intraoperative GT implant between 01/2019 and 12/2020. Data on gross tumor volume (GTV), number of GT units implanted, dose coverage for the high-risk clinical target volume (HR-CTV), measured by D90 or dose received by 90% of the HR-CTV, dose to organs at risk, and six months local control were collected.

Results: The median D90 to HR-CTV was 56.0 Gy (31.7-98.7 Gy). The brainstem, optic chiasm, ipsilateral optic nerve, and ipsilateral hippocampus median Dmax were 11.2, 5.4, 6.4, and 10.0 Gy, respectively. None of the patients in this study cohort suffered from radiation necrosis or adverse events attributable to the GT. Correlation was found between pre-op GTV, the volume of the resection cavity, and the number of GT units implanted. Of the resection cavities, 7/21 (33%) of the cavity experienced shrinkage, 3/21 (14%) remained stable, and 11/21 (52%) of the cavities expanded on the 3-months post-resection/GT implant MRIs. D90 to HR-CTV was found to be associated with local recurrence at 6-month post GT implant, suggesting a dose response relationship (p = 0.026). The median local recurrence-free survival was 366.5 days (64-1,098 days), and a trend towards improved local recurrence-free survival was seen in patients with D90 to HR-CTV ≥ 56 Gy (p = 0.048).

Conclusions: Our pilot, institutional experience provides clinical outcome, dosimetric considerations, and offer technical guidance in the clinical implementation of GT brachytherapy.

Keywords: Brachytherapy; Dosimetry; GammaTile; Glioblastoma; Radiotherapy; Treatment planning.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Brown NF, Ottaviani D, Tazare J et al (2022) Survival Outcomes and Prognostic Factors in Glioblastoma. Cancers 14:3161. https://doi.org/10.3390/cancers14133161 - DOI - PubMed - PMC
    1. Mohammed S, Ajayakumar MDT (2022) Survival and quality of life analysis in glioblastoma multiforme with adjuvant chemoradiotherapy: a retrospective study. Rep Pract Oncol Radiother 27:1026–1036. https://doi.org/10.5603/RPOR.a2022.0113 - DOI - PubMed - PMC
    1. Rampling R (2004) The present and future management of malignant brain tumours: surgery, radiotherapy, chemotherapy. J Neurol Neurosurg Psychiatry 75:ii24–ii30. https://doi.org/10.1136/jnnp.2004.040535 - DOI - PubMed - PMC
    1. Stupp R, Mason WP, Van Den Bent MJ et al (2005) Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330 - DOI - PubMed
    1. Gupta K, Burns TC (2018) Radiation-Induced Alterations in the Recurrent Glioblastoma Microenvironment: Therapeutic Implications. Front Oncol 8:503. https://doi.org/10.3389/fonc.2018.00503 - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources